Insulin glargine 300 IU/mL vs insulin degludec or sometimes it is more difficult to choose from two excellent options than from two bad ones
Abstract
Insulin glargine 300 IU/mL and insulin degludec belong to the long-acting second-generation insulin analogues that have, in comparison with long-acting first-generation insulin analogues, a longer half-life, lower risk of hypoglycemia and enhanced flexibility of time range of administration. The efficacy and safety of glargine 300 IU/mL and degludec were directly compared in the BRIGHT and the CONCLUDE trials.
These trials and their subsequent analyzes showed that the rate of HbA1c reduction was similar with both insulins, with glargine 300 IU/mL appearing to be more effective in certain subgroups of patients (glomerular filtration rate = 70 years), this difference, however, was not seen in the CONCLUDE trial. A slightly higher dose of glargine was not associated with a higher risk of hypoglycemia (on the contrary, according to the BRIGHT study, their incidence was even lower in the titration phase) or with an increase in body weight.
The efficacy of both insulins in patients with type 1 diabetes is being investigated in the currently ongoing InRange trial.